Analytical Data
-
Gene name
RIHB
- Application
-
Alternative Names
Retinoic acid-induced heparin-binding protein (RI-HB)
-
Species
Chicken
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P24052
-
Expression Region
22-142aa
-
Molecular Weight
20.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of recombinant Interleukin-1 receptor antagonist (RIHB) protein has gained significant attention due to its potential therapeutic applications in various inflammatory diseases. Interleukin-1 (IL-1) is a pro-inflammatory cytokine that plays a pivotal role in the immune response; however, its overproduction is associated with a range of conditions such as rheumatoid arthritis, osteoarthritis, and other autoimmune disorders. The IL-1 receptor antagonist (IL-1Ra) acts as a natural inhibitor of IL-1-signaling pathways, thus mitigating inflammatory responses. The recombinant form of this antagonist, RIHB, is produced through genetic engineering techniques that allow for high-yield expression in host systems such as bacteria or yeast. This approach not only enhances the availability of IL-1Ra for research and therapeutic use but also ensures consistent quality and safety. Studies have shown that RIHB can effectively reduce inflammation and tissue damage in preclinical models, paving the way for clinical trials aimed at evaluating its efficacy and safety in humans. Additionally, understanding the molecular mechanisms of RIHB can lead to the development of novel anti-inflammatory therapies and contribute to the broader field of immunology and receptor signaling. As researchers continue to explore the diverse applications of RIHB, its promise as a key player in managing chronic inflammatory disorders remains a focal point in biomedical research.
